Network Pharmacology-Based and Clinically Relevant Prediction of the Potential Targets of Chinese Herbs in Ovarian Cancer Patients

الملخص EN

Reports increasingly suggest that Chinese herbal medicine (CHM) has been used to treat ovarian cancer (OvCa) with a good curative effect; however, the molecular mechanisms underlying CHM are still unclear.

In this retrospective study, we explored CHM’s molecular targets for the treatment of OvCa based on clinical data and network pharmacology.

We used the Kaplan-Meier method and Cox regression analysis to verify the survival rate of 202 patients with CHM-treated OvCa.

The association between CHM and survival time was analyzed by bivariate correlation.

A target network of CHM active ingredients against OvCa was established via network pharmacology.

Cox regression analysis showed that CHM is an independent favorable prognostic factor.

The median survival time was 91 months in the CHM group and 65 months in the non-CHM group.

The survival time of FIGO stage III patients in the two groups was 91 months and 52 months, and the median survival period of FIOG stage IV patients was 60 months and 22 months, respectively (p<0.001).

Correlation analysis demonstrated that 12 herbs were closely associated with prognosis, especially in regard to the long-term benefits.

Bioinformatics analysis indicated that the anti-OvCa activity of these 12 herbs occurs mainly through the regulation of apoptosis-related protein expression, which promotes OvCa cell apoptosis and inhibits OvCa development.

They also regulate the progress of OvCa treatment by promoting or inhibiting protein expression on the p53 signaling pathway and by inhibiting the NF-κB signaling pathway by directly inhibiting NF-κB.